Epigenetic regulation of F2RL3 associates with myocardial infarction and platelet function

Laura J Corbin; Stephen J White; Amy E Taylor; Christopher M Williams; Kurt Taylor; Marion T J Van Den Bosch; Jack E Teasdale; Matthew L Jones; Mark Bond; Matthew T Harper; Louise Falk; Alex Groom; Georgina G J Hazell; Lavinia Paternoster; Marcus R Munafo; Børge G. Nordestgaard; Anne Tybjaerg-Hansen; Stig E Bojesen; Caroline L Relton; Josine L Min; George Davey Smith; Andrew D Mumford; Alastair W Poole; Nicholas John Timpson

doi:10.1161/CIRCRESAHA.121.318836

Epigenetic regulation of F2RL3 associates with myocardial infarction and platelet function

Laura J Corbin^*, Stephen J White, Amy E Taylor, Christopher M Williams, Kurt Taylor, Marion T J Van Den Bosch, Jack E Teasdale, Matthew L Jones, Mark Bond, Matthew T Harper, Louise Falk, Alex Groom, Georgina G J Hazell, Lavinia Paternoster, Marcus R Munafo, Børge G. Nordestgaard, Anne Tybjaerg-Hansen, Stig E Bojesen, Caroline L Relton, Josine L MinGeorge Davey Smith, Andrew D Mumford, Alastair W Poole, Nicholas John Timpson

^*Corresponding author for this work

Research output: Contribution to journal › Article (Academic Journal) › peer-review

17 Citations (Scopus)

101 Downloads (Pure)

Abstract

Background: DNA hypomethylation at the F2RL3 locus has been associated with both smoking and atherosclerotic cardiovascular disease; whether these smoking-related associations form a pathway to disease is unknown. F2RL3 encodes protease-activated receptor 4, a potent thrombin receptor expressed on platelets. Given the role of thrombin in platelet activation and the role of thrombus formation in myocardial infarction, alterations to this biological pathway could be important for ischemic cardiovascular disease.
Methods: We conducted multiple independent experiments to assess whether DNA hypomethylation at F2RL3 in response to smoking is associated with risk of myocardial infarction via changes to platelet reactivity. Using cohort data (N=3,205), we explored the relationship between smoking, DNA hypomethylation at F2RL3 and myocardial infarction. We compared platelet reactivity in individuals with low versus high DNA methylation at F2RL3 (N=41). We used an in vitro model to explore the biological response of F2RL3 to cigarette smoke extract (CSE). Finally, a series of reporter constructs were used to investigate how differential methylation could impact F2RL3 gene expression.
Results: Observationally, DNA methylation at F2RL3 mediated an estimated 34% of the smoking effect on increased risk of myocardial infarction. An association between methylation group (low/high) and platelet reactivity was observed in response to PAR4 stimulation. In cells, CSE exposure was associated with a 4.9 to 9.3% reduction in DNA methylation at F2RL3 and a corresponding 1.7 (95% CI: 1.2, 2.4, p=0.04) fold increase in F2RL3 mRNA. Results from reporter assays suggest the exon 2 region of F2RL3 may help control gene expression.
Conclusions: Smoking-induced epigenetic DNA hypomethylation at F2RL3 appears to increase PAR4 expression with potential downstream consequences for platelet reactivity. Combined evidence here not only identifies F2RL3 DNA methylation as a possible contributory pathway from smoking to cardiovascular disease risk, but from any feature potentially influencing F2RL3 regulation in a similar manner.

Original language	English
Pages (from-to)	384-400
Number of pages	17
Journal	Circulation Research
Volume	130
Issue number	3
Early online date	11 Jan 2022
DOIs	https://doi.org/10.1161/CIRCRESAHA.121.318836
Publication status	Published - 4 Feb 2022

Bibliographical note

Funding Information:
This work was specifically supported by the Medical Research Council (MRC) Integrative Epidemiology Unit (IEU; MC_UU_12013/3). N.J. Timpson is a Wellcome Trust (WT) Investigator (202802/Z/16/Z), is the PI of the Avon Longitudinal Study of Parents and Children (MRC and WT 217065/Z/19/Z), is supported by the University of Bristol NIHR Biomedical Research Centre (BRC-1215-2001), the MRC Integrative Epidemiology Unit (MC_UU_00011/1) and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A29019). N.J. Timpson, L.J. Corbin, A.E. Taylor, C. Relton, and G. Davey Smith work in the MRC IEU at the University of Bristol which is supported by the MRC (MC_UU_00011/1, MC_UU_00011/5) and the University of Bristol. C. Relton is supported by the Cancer Research UK (CRUK) Integrative Cancer Epidemiology Programme (C18281/A29019). G. Davey Smith and A.W. Poole are funded by the British Heart Foundation (BHF; AA/18/1/34219). A.W. Poole is a Wellcome Trust Investigator (219472/Z/19/Z). K. Taylor is a BHF funded PhD student (FS/17/60/33474). This study was supported by the NIHR Biomedical Research Centre at the University Hospitals Bristol National Health Service (NHS) Foundation Trust and the University of Bristol. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The study was supported by the NIHR Bristol Biomedical Research Unit in Cardiovascular Medicine and by BHF, grants PG/11/44/28972, FS/12/77/29887 and CH95/001. Funding was also provided by programme and project support from the BHF to AWP (RG/15/16/31758, PG/15/96/31854, PG/13/14/30023). This research was funded in whole, or in part, by the Wellcome Trust [202802/Z/16/Z]. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

Funding Information:
We would like to acknowledge the following people from University of Bristol for their contribution to this work: Elizabeth Aitken for her contribution to the laboratory work which is presented in the In vitro association between smoking and F2RL3 DNA hypomethylation and expression section of the methods; Ana Goncalves Soares for advice regarding statistical analysis; David Hughes for his contribution to figure generation. We are grateful to the Bristol Proteomics Facility for assistance with this work, and the expertise provided by Dr Kate Heesom and Dr Phil Lewis. This study makes use of data generated by the Blueprint Consortium. A full list of the investigators who contributed to the generation of the data is available from www.blueprint-epigenome.eu . Funding for the project was provided by the European Union’s Seventh Framework Programme (FP7/2007- 2013) under grant agreement no. 282510 - BLUEPRINT. Avon Longitudinal Study of Parents and Children (ALSPAC): We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. The UK Medical Research Council and the Wellcome Trust (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. Copenhagen City Heart Study: We acknowledge participants and team of the Copenhagen City Heart Study. The Danish Heart Foundation and the Capital Region of Denmark supported the Copenhagen City Heart Study.

Publisher Copyright:
© 2022 The Authors.

Research Groups and Themes

ALSPAC
Physical and Mental Health
ICEP

Keywords

DNA methylation
epigenetics
smoking
myocardial infarction
ALSPAC
blood platelets
thrombin
tobacco

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1161/CIRCRESAHA.121.318836

Full-text PDF (final published version)
This is the final published version of the article (version of record). It first appeared online via Wolters Kluwer Health, at https://doi.org/10.1161/CIRCRESAHA.121.318836 . Please refer to any applicable terms of use of the publisher.
Final published version, 2.11 MBLicence: CC BY

Handle.net

Persistent link

Embargoed Document

Full-text PDF (accepted author manuscript)
Accepted author manuscript, 1.35 MB
Request copy

1 Active
2 Finished

8074 (C18281/A29019) ICEP2 - Programme Award: Towards improved casual evidence and enhanced prediction of cancer risk and survival
Martin, R. M. (Principal Investigator)
1/10/20 → 30/09/25
Project: Research
IEU: MRC Integrative Epidemiology Unit Quinquennial renewal
Gaunt, L. F. (Principal Investigator) & Davey Smith, G. (Principal Investigator)
1/04/18 → 31/03/23
Project: Research
IEU - UWA 3
Timpson, N. J. (Principal Investigator) & Timpson, N. J. (Principal Investigator)
1/06/13 → 31/03/18
Project: Research

Epigenetic regulation of F2RL3 in vitro in response to exposure to cigarette smoke extract
Corbin, L. (Creator), Williams, C. M. (Creator), White, S. J. (Creator), Taylor, A. (Creator), Taylor, K. (Creator), Poole, A. (Contributor), Timpson, N. (Contributor) & Mumford, A. (Contributor), University of Bristol, 23 Dec 2021
DOI: 10.5523/bris.35olm77woaku72652wg0g0j6nf, http://data.bris.ac.uk/data/dataset/35olm77woaku72652wg0g0j6nf
Dataset

Cite this

Corbin, L. J., White, S. J., Taylor, A. E., Williams, C. M., Taylor, K., Van Den Bosch, M. T. J., Teasdale, J. E., Jones, M. L., Bond, M., Harper, M. T., Falk, L., Groom, A., Hazell, G. G. J., Paternoster, L., Munafo, M. R., Nordestgaard, B. G., Tybjaerg-Hansen, A., Bojesen, S. E., Relton, C. L., ... Timpson, N. J. (2022). Epigenetic regulation of F2RL3 associates with myocardial infarction and platelet function. Circulation Research, 130(3), 384-400. https://doi.org/10.1161/CIRCRESAHA.121.318836

@article{5e115c296f574bb4a1c1b886159faf72,

title = "Epigenetic regulation of F2RL3 associates with myocardial infarction and platelet function",

abstract = "Background: DNA hypomethylation at the F2RL3 locus has been associated with both smoking and atherosclerotic cardiovascular disease; whether these smoking-related associations form a pathway to disease is unknown. F2RL3 encodes protease-activated receptor 4, a potent thrombin receptor expressed on platelets. Given the role of thrombin in platelet activation and the role of thrombus formation in myocardial infarction, alterations to this biological pathway could be important for ischemic cardiovascular disease. Methods: We conducted multiple independent experiments to assess whether DNA hypomethylation at F2RL3 in response to smoking is associated with risk of myocardial infarction via changes to platelet reactivity. Using cohort data (N=3,205), we explored the relationship between smoking, DNA hypomethylation at F2RL3 and myocardial infarction. We compared platelet reactivity in individuals with low versus high DNA methylation at F2RL3 (N=41). We used an in vitro model to explore the biological response of F2RL3 to cigarette smoke extract (CSE). Finally, a series of reporter constructs were used to investigate how differential methylation could impact F2RL3 gene expression. Results: Observationally, DNA methylation at F2RL3 mediated an estimated 34% of the smoking effect on increased risk of myocardial infarction. An association between methylation group (low/high) and platelet reactivity was observed in response to PAR4 stimulation. In cells, CSE exposure was associated with a 4.9 to 9.3% reduction in DNA methylation at F2RL3 and a corresponding 1.7 (95% CI: 1.2, 2.4, p=0.04) fold increase in F2RL3 mRNA. Results from reporter assays suggest the exon 2 region of F2RL3 may help control gene expression.Conclusions: Smoking-induced epigenetic DNA hypomethylation at F2RL3 appears to increase PAR4 expression with potential downstream consequences for platelet reactivity. Combined evidence here not only identifies F2RL3 DNA methylation as a possible contributory pathway from smoking to cardiovascular disease risk, but from any feature potentially influencing F2RL3 regulation in a similar manner. ",

keywords = "DNA methylation, epigenetics, smoking, myocardial infarction, ALSPAC, blood platelets, thrombin, tobacco",

author = "Corbin, {Laura J} and White, {Stephen J} and Taylor, {Amy E} and Williams, {Christopher M} and Kurt Taylor and {Van Den Bosch}, {Marion T J} and Teasdale, {Jack E} and Jones, {Matthew L} and Mark Bond and Harper, {Matthew T} and Louise Falk and Alex Groom and Hazell, {Georgina G J} and Lavinia Paternoster and Munafo, {Marcus R} and Nordestgaard, {B{\o}rge G.} and Anne Tybjaerg-Hansen and Bojesen, {Stig E} and Relton, {Caroline L} and Min, {Josine L} and {Davey Smith}, George and Mumford, {Andrew D} and Poole, {Alastair W} and Timpson, {Nicholas John}",

note = "Funding Information: This work was specifically supported by the Medical Research Council (MRC) Integrative Epidemiology Unit (IEU; MC_UU_12013/3). N.J. Timpson is a Wellcome Trust (WT) Investigator (202802/Z/16/Z), is the PI of the Avon Longitudinal Study of Parents and Children (MRC and WT 217065/Z/19/Z), is supported by the University of Bristol NIHR Biomedical Research Centre (BRC-1215-2001), the MRC Integrative Epidemiology Unit (MC_UU_00011/1) and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A29019). N.J. Timpson, L.J. Corbin, A.E. Taylor, C. Relton, and G. Davey Smith work in the MRC IEU at the University of Bristol which is supported by the MRC (MC_UU_00011/1, MC_UU_00011/5) and the University of Bristol. C. Relton is supported by the Cancer Research UK (CRUK) Integrative Cancer Epidemiology Programme (C18281/A29019). G. Davey Smith and A.W. Poole are funded by the British Heart Foundation (BHF; AA/18/1/34219). A.W. Poole is a Wellcome Trust Investigator (219472/Z/19/Z). K. Taylor is a BHF funded PhD student (FS/17/60/33474). This study was supported by the NIHR Biomedical Research Centre at the University Hospitals Bristol National Health Service (NHS) Foundation Trust and the University of Bristol. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The study was supported by the NIHR Bristol Biomedical Research Unit in Cardiovascular Medicine and by BHF, grants PG/11/44/28972, FS/12/77/29887 and CH95/001. Funding was also provided by programme and project support from the BHF to AWP (RG/15/16/31758, PG/15/96/31854, PG/13/14/30023). This research was funded in whole, or in part, by the Wellcome Trust [202802/Z/16/Z]. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. Funding Information: We would like to acknowledge the following people from University of Bristol for their contribution to this work: Elizabeth Aitken for her contribution to the laboratory work which is presented in the In vitro association between smoking and F2RL3 DNA hypomethylation and expression section of the methods; Ana Goncalves Soares for advice regarding statistical analysis; David Hughes for his contribution to figure generation. We are grateful to the Bristol Proteomics Facility for assistance with this work, and the expertise provided by Dr Kate Heesom and Dr Phil Lewis. This study makes use of data generated by the Blueprint Consortium. A full list of the investigators who contributed to the generation of the data is available from www.blueprint-epigenome.eu . Funding for the project was provided by the European Union{\textquoteright}s Seventh Framework Programme (FP7/2007- 2013) under grant agreement no. 282510 - BLUEPRINT. Avon Longitudinal Study of Parents and Children (ALSPAC): We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. The UK Medical Research Council and the Wellcome Trust (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. Copenhagen City Heart Study: We acknowledge participants and team of the Copenhagen City Heart Study. The Danish Heart Foundation and the Capital Region of Denmark supported the Copenhagen City Heart Study. Publisher Copyright: {\textcopyright} 2022 The Authors.",

year = "2022",

month = feb,

day = "4",

doi = "10.1161/CIRCRESAHA.121.318836",

language = "English",

volume = "130",

pages = "384--400",

journal = "Circulation Research",

issn = "0009-7330",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

Corbin, LJ, White, SJ, Taylor, AE , Williams, CM, Taylor, K, Van Den Bosch, MTJ, Teasdale, JE, Jones, ML, Bond, M, Harper, MT, Falk, L, Groom, A, Hazell, GGJ, Paternoster, L, Munafo, MR, Nordestgaard, BG, Tybjaerg-Hansen, A, Bojesen, SE, Relton, CL, Min, JL , Davey Smith, G , Mumford, AD , Poole, AW & Timpson, NJ 2022, 'Epigenetic regulation of F2RL3 associates with myocardial infarction and platelet function', Circulation Research, vol. 130, no. 3, pp. 384-400. https://doi.org/10.1161/CIRCRESAHA.121.318836

TY - JOUR

T1 - Epigenetic regulation of F2RL3 associates with myocardial infarction and platelet function

AU - Corbin, Laura J

AU - White, Stephen J

AU - Taylor, Amy E

AU - Williams, Christopher M

AU - Taylor, Kurt

AU - Van Den Bosch, Marion T J

AU - Teasdale, Jack E

AU - Jones, Matthew L

AU - Bond, Mark

AU - Harper, Matthew T

AU - Falk, Louise

AU - Groom, Alex

AU - Hazell, Georgina G J

AU - Paternoster, Lavinia

AU - Munafo, Marcus R

AU - Nordestgaard, Børge G.

AU - Tybjaerg-Hansen, Anne

AU - Bojesen, Stig E

AU - Relton, Caroline L

AU - Min, Josine L

AU - Davey Smith, George

AU - Mumford, Andrew D

AU - Poole, Alastair W

AU - Timpson, Nicholas John

N1 - Funding Information: This work was specifically supported by the Medical Research Council (MRC) Integrative Epidemiology Unit (IEU; MC_UU_12013/3). N.J. Timpson is a Wellcome Trust (WT) Investigator (202802/Z/16/Z), is the PI of the Avon Longitudinal Study of Parents and Children (MRC and WT 217065/Z/19/Z), is supported by the University of Bristol NIHR Biomedical Research Centre (BRC-1215-2001), the MRC Integrative Epidemiology Unit (MC_UU_00011/1) and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A29019). N.J. Timpson, L.J. Corbin, A.E. Taylor, C. Relton, and G. Davey Smith work in the MRC IEU at the University of Bristol which is supported by the MRC (MC_UU_00011/1, MC_UU_00011/5) and the University of Bristol. C. Relton is supported by the Cancer Research UK (CRUK) Integrative Cancer Epidemiology Programme (C18281/A29019). G. Davey Smith and A.W. Poole are funded by the British Heart Foundation (BHF; AA/18/1/34219). A.W. Poole is a Wellcome Trust Investigator (219472/Z/19/Z). K. Taylor is a BHF funded PhD student (FS/17/60/33474). This study was supported by the NIHR Biomedical Research Centre at the University Hospitals Bristol National Health Service (NHS) Foundation Trust and the University of Bristol. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The study was supported by the NIHR Bristol Biomedical Research Unit in Cardiovascular Medicine and by BHF, grants PG/11/44/28972, FS/12/77/29887 and CH95/001. Funding was also provided by programme and project support from the BHF to AWP (RG/15/16/31758, PG/15/96/31854, PG/13/14/30023). This research was funded in whole, or in part, by the Wellcome Trust [202802/Z/16/Z]. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. Funding Information: We would like to acknowledge the following people from University of Bristol for their contribution to this work: Elizabeth Aitken for her contribution to the laboratory work which is presented in the In vitro association between smoking and F2RL3 DNA hypomethylation and expression section of the methods; Ana Goncalves Soares for advice regarding statistical analysis; David Hughes for his contribution to figure generation. We are grateful to the Bristol Proteomics Facility for assistance with this work, and the expertise provided by Dr Kate Heesom and Dr Phil Lewis. This study makes use of data generated by the Blueprint Consortium. A full list of the investigators who contributed to the generation of the data is available from www.blueprint-epigenome.eu . Funding for the project was provided by the European Union’s Seventh Framework Programme (FP7/2007- 2013) under grant agreement no. 282510 - BLUEPRINT. Avon Longitudinal Study of Parents and Children (ALSPAC): We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. The UK Medical Research Council and the Wellcome Trust (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. Copenhagen City Heart Study: We acknowledge participants and team of the Copenhagen City Heart Study. The Danish Heart Foundation and the Capital Region of Denmark supported the Copenhagen City Heart Study. Publisher Copyright: © 2022 The Authors.

PY - 2022/2/4

Y1 - 2022/2/4

N2 - Background: DNA hypomethylation at the F2RL3 locus has been associated with both smoking and atherosclerotic cardiovascular disease; whether these smoking-related associations form a pathway to disease is unknown. F2RL3 encodes protease-activated receptor 4, a potent thrombin receptor expressed on platelets. Given the role of thrombin in platelet activation and the role of thrombus formation in myocardial infarction, alterations to this biological pathway could be important for ischemic cardiovascular disease. Methods: We conducted multiple independent experiments to assess whether DNA hypomethylation at F2RL3 in response to smoking is associated with risk of myocardial infarction via changes to platelet reactivity. Using cohort data (N=3,205), we explored the relationship between smoking, DNA hypomethylation at F2RL3 and myocardial infarction. We compared platelet reactivity in individuals with low versus high DNA methylation at F2RL3 (N=41). We used an in vitro model to explore the biological response of F2RL3 to cigarette smoke extract (CSE). Finally, a series of reporter constructs were used to investigate how differential methylation could impact F2RL3 gene expression. Results: Observationally, DNA methylation at F2RL3 mediated an estimated 34% of the smoking effect on increased risk of myocardial infarction. An association between methylation group (low/high) and platelet reactivity was observed in response to PAR4 stimulation. In cells, CSE exposure was associated with a 4.9 to 9.3% reduction in DNA methylation at F2RL3 and a corresponding 1.7 (95% CI: 1.2, 2.4, p=0.04) fold increase in F2RL3 mRNA. Results from reporter assays suggest the exon 2 region of F2RL3 may help control gene expression.Conclusions: Smoking-induced epigenetic DNA hypomethylation at F2RL3 appears to increase PAR4 expression with potential downstream consequences for platelet reactivity. Combined evidence here not only identifies F2RL3 DNA methylation as a possible contributory pathway from smoking to cardiovascular disease risk, but from any feature potentially influencing F2RL3 regulation in a similar manner.

AB - Background: DNA hypomethylation at the F2RL3 locus has been associated with both smoking and atherosclerotic cardiovascular disease; whether these smoking-related associations form a pathway to disease is unknown. F2RL3 encodes protease-activated receptor 4, a potent thrombin receptor expressed on platelets. Given the role of thrombin in platelet activation and the role of thrombus formation in myocardial infarction, alterations to this biological pathway could be important for ischemic cardiovascular disease. Methods: We conducted multiple independent experiments to assess whether DNA hypomethylation at F2RL3 in response to smoking is associated with risk of myocardial infarction via changes to platelet reactivity. Using cohort data (N=3,205), we explored the relationship between smoking, DNA hypomethylation at F2RL3 and myocardial infarction. We compared platelet reactivity in individuals with low versus high DNA methylation at F2RL3 (N=41). We used an in vitro model to explore the biological response of F2RL3 to cigarette smoke extract (CSE). Finally, a series of reporter constructs were used to investigate how differential methylation could impact F2RL3 gene expression. Results: Observationally, DNA methylation at F2RL3 mediated an estimated 34% of the smoking effect on increased risk of myocardial infarction. An association between methylation group (low/high) and platelet reactivity was observed in response to PAR4 stimulation. In cells, CSE exposure was associated with a 4.9 to 9.3% reduction in DNA methylation at F2RL3 and a corresponding 1.7 (95% CI: 1.2, 2.4, p=0.04) fold increase in F2RL3 mRNA. Results from reporter assays suggest the exon 2 region of F2RL3 may help control gene expression.Conclusions: Smoking-induced epigenetic DNA hypomethylation at F2RL3 appears to increase PAR4 expression with potential downstream consequences for platelet reactivity. Combined evidence here not only identifies F2RL3 DNA methylation as a possible contributory pathway from smoking to cardiovascular disease risk, but from any feature potentially influencing F2RL3 regulation in a similar manner.

KW - DNA methylation

KW - epigenetics

KW - smoking

KW - myocardial infarction

KW - ALSPAC

KW - blood platelets

KW - thrombin

KW - tobacco

U2 - 10.1161/CIRCRESAHA.121.318836

DO - 10.1161/CIRCRESAHA.121.318836

M3 - Article (Academic Journal)

C2 - 35012325

SN - 0009-7330

VL - 130

SP - 384

EP - 400

JO - Circulation Research

JF - Circulation Research

IS - 3

ER -

Epigenetic regulation of F2RL3 associates with myocardial infarction and platelet function

Abstract

Bibliographical note

Research Groups and Themes

Keywords

UN SDGs

Access to Document

Handle.net

Embargoed Document

Fingerprint

Projects

8074 (C18281/A29019) ICEP2 - Programme Award: Towards improved casual evidence and enhanced prediction of cancer risk and survival

IEU: MRC Integrative Epidemiology Unit Quinquennial renewal

IEU - UWA 3

Datasets

Epigenetic regulation of F2RL3 in vitro in response to exposure to cigarette smoke extract

Cite this